Nigerian pharma tycoon Fidelis Ayebae’s Fidson posts $3.41 million profit in 2024
This growth was driven by a surge in sales of ethical and OTC products, reinforcing Fidson’s position as a top player in Nigeria’s pharmaceutical industry.
Nigerian pharma tycoon
Nigerian pharma tycoon Fidelis Ayebae's Fidson receives support to expand production capacity
The collaboration with NEXIM is expected to position Fidson for a stronger presence in Africa's rapidly expanding pharmaceutical market.
Fidson, owned by Fidelis Ayebae, plans $100-million medicine production plant in Lekki FTZ
This move aligns with the company’s efforts to bolster Nigeria’s self-sufficiency in healthcare, focusing on combating the country's ongoing HIV crisis.
Nigerian pharma tycoon Fidelis Ayebae’s stake in Fidson is now worth $14.8 million
Under Ayebae’s guidance, Fidson Healthcare has achieved exceptional financial growth, reporting a significant increase in profits for the 2022 fiscal year.
Nigerian pharma tycoon Fidelis Ayebae’s Fidson smashes expectations with $9.08-million profit
Fidson Healthcare has established itself as a leading player in the Nigerian and West African pharmaceutical industries.